REG - AstraZeneca PLC - AZN: Year-To-Date and Q3 2017 Results Announcement <Origin Href="QuoteRef">AZN.L</Origin> - Part 4
09/11/2017 07:08
- Part 4: For the preceding part double click ID:nRSI9871Vc
available for sale gains taken to equity 58 162
Tax on items that may be reclassified subsequently to profit or loss (55) (12)
410 (103)
Other comprehensive income/(loss) for the period, net of tax 487 (367)
Total comprehensive income for the period 1,136 628
Profit attributable to:
Owners of the Parent 686 1,014
Non-controlling interests (37) (19)
649 995
Total comprehensive income attributable to:
Owners of the Parent 1,173 648
Non-controlling interests (37) (20)
1,136 628
Basic earnings per $0.25 Ordinary Share $0.54 $0.80
Diluted earnings per $0.25 Ordinary Share $0.54 $0.80
Weighted average number of Ordinary Shares in issue (millions) 1,266 1,265
Diluted weighted average number of Ordinary Shares in issue (millions) 1,267 1,266
Condensed Consolidated Statement of Financial Position
ASSETSNon-current assets
Property, plant and equipment 7,329 6,848 6,690
Goodwill 11,841 11,658 11,756
Intangible assets 27,124 27,586 28,507
Derivative financial instruments 440 343 278
Investments in associates and joint ventures 78 99 95
Other investments 1,004 727 715
Other receivables 953 901 681
Deferred tax assets 2,184 1,102 1,584
50,953 49,264 50,306
Current assets
Inventories 3,162 2,334 2,420
Assets held for sale - - 332
Trade and other receivables 4,540 4,573 5,449
Other investments 1,175 884 909
Derivative financial instruments - 27 26
Income tax receivable 721 426 640
Cash and cash equivalents 4,036 5,018 3,090
13,634 13,262 12,866
Total assets 64,587 62,526 63,172
LIABILITIESCurrent liabilities
Interest-bearing loans and borrowings (941) (2,307) (2,939)
Trade and other payables (10,832) (10,486) (9,961)
Derivative financial instruments (10) (18) (12)
Provisions (1,167) (1,065) (936)
Income tax payable (1,513) (1,380) (1,534)
(14,463) (15,256) (15,382)
Non-current liabilities
Interest-bearing loans and borrowings (16,911) (14,501) (14,744)
Derivative financial instruments (3) (117) (25)
Deferred tax liabilities (5,079) (3,956) (4,001)
Retirement benefit obligations (2,490) (2,186) (2,870)
Provisions (387) (353) (396)
Other payables (9,807) (9,488) (10,842)
(34,677) (30,601) (32,878)
Total liabilities (49,140) (45,857) (48,260)
Net assets 15,447 16,669 14,912
EQUITY
Capital and reserves attributable to equity holders of the Company
Share capital 316 316 316
Share premium account 4,381 4,351 4,344
Other reserves 2,027 2,047 2,031
Retained earnings 7,001 8,140 6,381
13,725 14,854 13,072
Non-controlling interests 1,722 1,815 1,840
Total equity 15,447 16,669 14,912
Total equity
15,447
16,669
14,912
*30 September comparatives have been restated to reflect an adjustment to the acquisition-accounting for Acerta Pharma (as
detailed in Note 4 of the Full Year and Fourth Quarter 2016 Results Announcement).
Condensed Consolidated Statement of Cash Flows
Cash flows from operating activities
Profit before tax 1,820 1,369
Finance income and expense 1,128 978
Share of after tax losses in associates and joint ventures 43 22
Depreciation, amortisation and impairment 1,929 1,767
Increase in working capital and short-term provisions (228) (472)
Gains on disposal of intangible assets (735) (198)
Fair value movements on contingent consideration arising from business combinations (62) 132
Non-cash and other movements (322) (479)
Cash generated from operations 3,573 3,119
Interest paid (519) (489)
Tax paid (473) (445)
Net cash inflow from operating activities 2,581 2,185
Cash flows from investing activities
Movement in short-term investments and fixed deposits (288) (165)
Purchase of property, plant and equipment (849) (912)
Disposal of property, plant and equipment 57 47
Purchase of intangible assets (220) (761)
Disposal of intangible assets 894 117
Purchase of non-current asset investments (91) (210)
Disposal of non-current asset investments 14 -
Payments to joint ventures (11) (19)
Upfront payments on business combinations - (2,564)
Payment of contingent consideration from business combinations (310) (197)
Interest received 118 105
Payments made by subsidiaries to non-controlling interests - (13)
Net cash outflow from investing activities (686) (4,572)
Net cash inflow/(outflow) before financing activities 1,895 (2,387)
Cash flows from financing activities
Proceeds from issue of share capital 30 40
Issue of loans 1,988 2,483
Repayment of loans (1,750) -
Dividends paid (3,519) (3,561)
Hedge contracts relating to dividend payments (20) 18
Repayment of obligations under finance leases (14) (12)
Movement in short-term borrowings 361 12
Net cash outflow from financing activities (2,924) (1,020)
Net decrease in cash and cash equivalents in the period (1,029) (3,407)
Cash and cash equivalents at the beginning of the period 4,924 6,051
Exchange rate effects (71) 43
Cash and cash equivalents at the end of the period 3,824 2,687
Cash and cash equivalents consists of:
Cash and cash equivalents 4,036 3,090
Overdrafts (212) (403)
3,824 2,687
2,687
Condensed Consolidated Statement of Changes in Equity
Share Share Other Retained Total Non- Total
capital premium reserves* earnings $m controlling equity
$m account $m $m interests $m
$m $m
At 1 Jan 2016 316 4,304 2,036 11,834 18,490 19 18,509
Profit for the period - - - 1,657 1,657 (68) 1,589
Other comprehensive income - - - (1,645) (1,645) (1) (1,646)
Transfer to other reserves - - (5) 5 - - -
Transactions with owners:
Dividends - - - (3,540) (3,540) - (3,540)
Dividends paid by subsidiary to non-controlling interest - - - - - (13) (13)
Acerta put option - - - (1,825) (1,825) - (1,825)
Changes in non-controlling interest - - - - - 1,903 1,903
Issue of Ordinary Shares - 40 - - 40 - 40
Share-based payments - - - (105) (105) - (105)
Net movement - 40 (5) (5,453) (5,418) 1,821 (3,597)
At 30 Sep 2016 316 4,344 2,031 6,381 13,072 1,840 14,912
Share Share Other Retained Total Non- Total
capital premium reserves* earnings $m controlling equity
$m account $m $m interests $m
$m $m
At 1 Jan 2017 316 4,351 2,047 8,140 14,854 1,815 16,669
Profit for the period - - - 1,700 1,700 (93) 1,607
Other comprehensive income - - - 776 776 - 776
Transfer to other reserves - - (20) 20 - - -
Transactions with owners:
Dividends - - - (3,543) (3,543) - (3,543)
Issue of Ordinary Shares - 30 - - 30 - 30
Share-based payments - - - (92) (92) - (92)
Net movement - 30 (20) (1,139) (1,129) (93) (1,222)
At 30 Sep 2017 316 4,381 2,027 7,001 13,725 1,722 15,447
* Other reserves include the capital redemption reserve and the merger reserve.
Notes to the Interim Financial Statements
1 BASIS OF PREPARATION AND ACCOUNTING POLICIES
These unaudited condensed consolidated interim financial statements (interim financial statements) for the nine months
ended 30 September 2017 have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European
Union (EU) and as issued by the International Accounting Standards Board (IASB).
The annual financial statements of the Group are prepared in accordance with International Financial Reporting Standards
(IFRSs) as adopted by the EU and as issued by the IASB. The interim financial statements have been prepared applying the
accounting policies and presentation that were applied in the preparation of the Group's published consolidated financial
statements for the year ended 31 December 2016. There have been no significant new or revised accounting standards applied
in the nine months ended 30 September 2017.
We have revised the balance sheet presentation of deferred tax with effect from 1 January 2017 with no impact upon net
deferred tax, balance sheet net assets, the cash flow statement or the income statement. This presentation change has
resulted in us showing gross, rather than net, deferred tax assets and deferred tax liabilities of a group entity. This
change has been made as that entity has transactions that are subject to tax by two different taxation authorities and has
the effect of separately disclosing the deferred tax effects for each country. The comparative balance sheet has not been
revised for this presentational change. If the 31 December 2016 and 30 September 2016 balances were presented in a
comparable way the deferred tax assets would have been $2,093m and $2,234m, respectively. The deferred tax liabilities
would have been $4,947m and $4,701m, respectively.
As disclosed in our 2016 Annual Report on Page 181, the Group has entered into a number of financial derivative
transactions with commercial banks. The Group has agreements with some bank counterparties whereby the parties agree to
post cash collateral, for the benefit of the other, equivalent to the market valuation of the derivative positions above a
predetermined threshold. We have revised the balance sheet presentation of these collateral balances with effect from 1
January 2017, so that the cash collateral is included in cash and cash equivalents, with an offsetting liability presented
in current interest-bearing loans and borrowings. This revision has no impact on our balance sheet net assets, or the
income statement. The comparative balance sheet has not been revised for this presentational change. If the 31 December
2016 and 30 September 2016 balances were presented in a comparable way the cash and cash equivalents balance would have
been $5,260m and $3,345m, respectively. Current interest-bearing loans and borrowings would have been $2,549m and $3,194m,
respectively.
Legal proceedings
The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form 20-F Information 2016 and interim financial statements for the six months ended 30 June
2017.
Going concern
The Group has considerable financial resources available. As at 30 September 2017 the Group has $6.1bn in financial
resources (cash balances of $4bn and undrawn committed bank facilities of $3bn which are available until April 2022, with
only $0.9bn of debt due within one year). The Group's revenues are largely derived from sales of products which are covered
by patents which provide a relatively high level of resilience and predictability to cash inflows, although our revenue is
expected to continue to be significantly impacted by the expiry of patents over the medium term. In addition, government
price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in many of
our mature markets. However, we anticipate new revenue streams from both recently launched medicines and products in
development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently,
the Directors believe that, overall, the Group is well placed to manage its business risks successfully.
On the basis of the above paragraph, the going concern basis has been adopted in these interim financial statements.
Financial information
This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and
435(3) of the Companies Act 2006. The Group's accounts for 2016 were published in the Annual Report 2016, which has been
delivered to the registrar of companies. The report of the auditors, KPMG LLP, was (i) unqualified, (ii) did not include a
reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii)
did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
2 RESTRUCTURING COSTS
Profit before tax for the nine months ended 30 September 2017 is stated after charging restructuring costs of $645m ($250m
for the YTD ended 30 September 2016). These have been charged to profit as follows:
YTD 2017 YTD 2016 Q3 2017 Q3 2016
$m $m $m $m
Cost of sales 128 87 47 59
Research and development expense 177 146 35 39
Selling, general and administrative costs 265 504 68 176
Other operating income and expense 75 (24) (1) (24)
Total 645 713 149 250
3 NET DEBT
The table below provides an analysis of net debt and a reconciliation of net cash flow to the movement in net debt.
The Group monitors net debt as part of its capital management policy as described in Note 26 of the Annual Report and Form
20-F Information 2016.
At 1 Jan 2017 $m Cash Flow $m Non-cash& Other$m Exchange Movements$m At 30 Sep 2017 $m
Loans due after one year (14,495) (1,988) (7) (420) (16,910)
Finance leases due after one year (6) - 5 - (1)
Total long-term debt (14,501) (1,988) (2) (420) (16,911)
Current instalments of loans (1,769) 1,750 19 - -
Current instalments of finance leases (87) 14 63 (1) (11)
Total current debt (1,856) 1,764 82 (1) (11)
Other investments - current 884 288 - 3 1,175
Other investments - non-current 14 66 - - 80
Net derivative financial instruments 235 20 172 - 427
Cash and cash equivalents 5,018 (913) - (69) 4,036
Overdrafts (94) (116) - (2) (212)
Short-term borrowings (357) (361) - - (718)
5,700 (1,016) 172 (68) 4,788
Net debt (10,657) (1,240) 252 (489) (12,134)
Non-cash movements in the period include fair value adjustments under IAS 39.
4 FINANCIAL INSTRUMENTS
As detailed in the Group's most recent annual financial statements, our principal financial instruments consist of
derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and
other payables, and interest-bearing loans and borrowings. The accounting policies for financial instruments, including
fair value measurement, can be found on pages 144 and 145 of the Company's Annual Report and Form 20-F Information 2016.
There have been no significant new or revised accounting standards applied in the nine months ended 30 September 2017 and
there have been no changes of significance to the categorisation or fair value hierarchy classification of our financial
instruments. During the year, we revised the balance sheet presentation of cash collateral balances held with commercial
bank counterparties, effective from 1 January 2017 (see Note 1).
Financial instruments measured at fair value include $1,175m of other investments, $2,007m of loans, and $427m of
derivatives as at 30 September 2017. The total fair value of interest-bearing loans and borrowings at 30 September 2017
which have a carrying value of $17,852m in the Condensed Consolidated Statement of Financial Position, was $17,242m.
Contingent consideration liabilities arising on business combinations have been classified under Level 3 in the fair value
hierarchy and movements in fair value are shown below:
DiabetesAlliance2017 Other 2017 Total 2017 Total 2016
$m $m $m $m
At 1 January 4,240 1,217 5,457 6,411
Settlements (235) (75) (310) (197)
Revaluations (71) 9 (62) 132
Discount unwind 234 71 305 372
Foreign exchange - - - 2
At 30 September 4,168 1,222 5,390 6,720
5 LEGAL PROCEEDINGS AND CONTINGENT LIABILITIES
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and
investigations relating to product liability, commercial disputes, infringement of intellectual property rights, the
validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual
Report and Form 20-F Information 2016, the interim financial statements for the three months ended 31 March 2017 and the
interim financial statements for the three months ended 30 June 2017 (the Disclosures). Unless noted otherwise below or in
the Disclosures, no provisions have been established in respect of the claims discussed below.
As discussed in the Disclosures, for the majority of claims in which AstraZeneca is involved it is not possible to make a
reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings.
In these cases, AstraZeneca discloses information with respect only to the nature and facts of the cases but no provision
is made.
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, we record the
loss absorbed or make a provision for our best estimate of the expected loss.
The position could change over time and the estimates that we have made and upon which we have relied in calculating these
provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of
any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors
causing this uncertainty are described more fully in the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and enforce, its intellectual property.
Matters disclosed in respect of the third quarter of 2017 and to 9 November 2017.
Patent litigation
Faslodex (fulvestrant)
US patent proceedings
As previously disclosed, AstraZeneca has filed patent infringement lawsuits in the US District Court in New Jersey relating
to patents listed in the FDA Orange Book with reference to Faslodex after AstraZeneca received notice of Abbreviated New
Drug Applications (ANDA) seeking FDA approval to market generic versions of Faslodex prior to the expiration of
AstraZeneca's patents. As previously disclosed, AstraZeneca has resolved the lawsuits with several of the ANDA filers. In
October 2017, AstraZeneca resolved the lawsuit with an eighth ANDA filer.
In October 2017, AstraZeneca received a Paragraph IV notice regarding a New Drug Application submitted pursuant to 21
U.S.C. § 355(b)(2) by Fresenius Kabi USA LLC relating to the same FDA Orange Book-listed patents.
As previously disclosed, in February 2017, AstraZeneca was served with three petitions for inter partes review by the
Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office relating to FDA Orange Book-listed patents with
reference to Faslodex. In September 2017, the PTAB denied institution of all three petitions, and no appeals have been made
to date.
Imfinzi (durvalumab)
US patent proceedings
In July 2017, Bristol-Myers Squibb, E.R. Squibb & Sons L.L.C., Ono Pharmaceutical Co. and Tasuku Honjo filed a patent
infringement action in the US District Court in Delaware relating to AstraZeneca's commercialisation of Imfinzi in the US.
AstraZeneca filed an answer to the complaint in October 2017 alleging, inter alia, that the asserted patent is invalid and
not infringed. The litigation is ongoing.
Calquence (acalabrutinib)
US patent proceedings
In November 2017, Pharmacyclics LLC filed a complaint in the US District Court for the District of Delaware against Acerta
Pharma BV, Acerta Pharma LLC, and AstraZeneca Pharmaceuticals LP (collectively, AstraZeneca) alleging that AstraZeneca's
Calquence infringes certain claims of US Patent Nos. 9,079,908; 9,139,591; and 9,556,182. AstraZeneca will respond to the
complaint in due course.
Brilinta(ticagrelor)
Patent proceedings outside the US
In Canada, in June 2017, Teva Canada Limited challenged the patents listed on the Canadian Patent Register with reference
to Brilinta. In September 2017, Apotex Inc. did the same. AstraZeneca has commenced applications to respond to the
challenges.
In China, in October 2017, the Chinese Patent Office issued a decision invalidating one of AstraZeneca's Chinese substance
patents relating to Brilinta. The patent, Chinese Patent No. ZL99815926.3, is due to expire in December 2019. AstraZeneca
will appeal the decision.
Onglyza (saxagliptin) and Kombiglyze (saxagliptin and metformin)
US patent proceedings
As previously disclosed, in 2016, the US Patent and Trademark Office (USPTO) instituted an inter partes review brought by
several generic entities challenging the validity of US Patent No. RE44,186 (the '186 Patent), which is listed in the FDA
Orange Book with reference to Onglyza and Kombiglyze XR. In August 2017, the USPTO decided in AstraZeneca's favour and
upheld the challenged claims of the '186 Patent. In October 2017, the USPTO's decision was appealed.
Losec/Prilosec(omeprazole)
Patent proceedings outside the US
As previously disclosed, in Canada, in 2004, AstraZeneca brought proceedings against Apotex Inc. (Apotex) for infringement
of several patents related to Losec. In February 2015, the Federal Court of Canada (the Court) found that Apotex had
infringed AstraZeneca's Losec formulation patent (Canadian Patent No. 1,292,693). This finding was upheld on appeal. In
July 2017, after a reference to account for Apotex' profits earned as a result of the infringement, the Court issued its
decision describing how the quantification of monies owed to AstraZeneca should proceed. Apotex has appealed.
Product liability litigation
Onglyza (saxagliptin) and Kombiglyze (saxagliptin and metformin)
As previously disclosed, AstraZeneca is defending claims in the US brought by plaintiffs alleging heart failure, cardiac
failure and/or death from treatment with Onglyza and/or Kombiglyze. In October 2017, counsel for a group of such plaintiffs
filed a motion with the Judicial Panel on Multidistrict Litigation seeking the transfer of any currently pending federal
court cases as well as any similar, subsequently filed cases to a coordinated and consolidated pre-trial multidistrict
litigation proceeding.
Nexium (esomeprazole magnesium) and Losec/Prilosec (omeprazole)
As previously disclosed, in the US, AstraZeneca is defending various lawsuits involving multiple plaintiffs claiming that
they have been diagnosed with kidney injuries following treatment with proton pump inhibitors (PPIs), including Nexium and
Prilosec and, in May 2017, counsel for a group of such plaintiffs filed a motion with the Judicial Panel on Multidistrict
Litigation (JPML) seeking the transfer of any currently pending federal court cases as well as any similar, subsequently
filed cases to a coordinated and consolidated pre-trial multidistrict litigation (MDL) proceeding. In August 2017, the JPML
granted the motion and consolidated the pending federal court cases in an MDL proceeding in federal court in New Jersey for
pre-trial purposes.
In Canada, in July and August 2017, AstraZeneca was served with three putative class action lawsuits. Two of the lawsuits,
pending in Ontario and Saskatchewan, seek authorisation to represent individuals resident in Canada who allegedly suffered
kidney injuries from the use of proton pump inhibitors, including Nexium and Losec, and the third, pending in Quebec, seeks
authorisation to represent such individuals resident in Quebec.
Commercial litigation
Anti-Terrorism Act Civil Lawsuit
In the US, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as
defendants in a complaint filed in federal court in the District of Columbia by US nationals (or their estates, survivors,
or heirs) who were killed or wounded in Iraq between 2005 and 2009. The plaintiffs allege that the defendants violated the
US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of
Health.
Government investigations/proceedings
Seroquel IR (quetiapine fumarate) and SeroquelXR (quetiapine fumarate)
Texas Attorney General litigation
As previously disclosed, in the US, in October 2014, following a previously disclosed investigation by the State of Texas
(the State) into AstraZeneca's sales and marketing activities involving Seroquel, the Texas Attorney General's Office
intervened in a State whistleblower action pending in Travis County Court, Texas (the County Court). The lawsuit alleges
that AstraZeneca engaged in inappropriate promotion of Seroquel and made improper payments intended to influence the
formulary status of Seroquel. The relief that the State seeks to recover from AstraZeneca includes trebled civil remedies,
penalties, interest, and attorneys' fees pursuant to the Texas Medicaid Fraud Prevention Act) and damages pursuant to Texas
common law. In June 2017, the Court entered an order denying all of the State's motions for summary judgment except for the
State's motion on the defence of waiver, and denying AstraZeneca's motion for summary judgment.
The trial, which was scheduled for October 2017, has been postponed until after the Texas Supreme Court resolves the
appeals in unrelated cases called Nazari v. State and In re Xerox Corp. A provision has been taken with regard to claims
brought by the State and other related lawsuits.
Nexium (esomeprazole magnesium)
Federal Trade Commission inquiry
As previously disclosed, in the US, in 2008, AstraZeneca received a Civil Investigative Demand from the US Federal Trade
Commission (FTC) in 2008 seeking information regarding the Nexium patent litigation settlement with Ranbaxy Laboratories
Ltd. This investigation was officially closed by the FTC in October 2017.
6 product analysis - YTD 2017
The table below provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting
year-on-year growth.
World Emerging Markets US Europe Established ROW
YTD 2017$m Actual% CER% YTD 2017$m Actual% CER YTD 2017$m Actual% YTD 2017$m Actual% CER% YTD 2017$m Actual% CER%
%
Oncology
Tagrisso 651 136 138 85 n/m n/m 277 54 124 153 157 165 n/m n/m
Iressa 398 1 2 200 7 8 27 69 80 (12) (12) 91 (10) (9)
Lynparza 197 26 26 11 n/m n/m 87 (9) 94 68 70 5 n/m n/m
Imfinzi 1 n/m n/m - - - 1 n/m - - - - - -
Legacy:
Faslodex 703 16 16 88 26 23 368 15 194 15 16 53 10 13
Zoladex 548 (6) (5) 260 9 10 16 (41) 104 (11) (8) 168 (16) (15)
Casodex 161 (14) (12) 78 (5) (1) 1 (50) 17 (11) (11) 65 (23) (21)
Arimidex 160 (9) (6) 85 2 6 5 (58) 26 (4) (4) 44 (17) (15)
Others 85 13 16 21 5 10 - - 4 - - 60 18 20
Total Oncology 2,904 18 19 828 20 22 782 20 643 21 23 651 12 14
CVMD
Brilinta 780 29 31 175 29 32 355 46 213 11 13 37 16 13
Farxiga 742 24 24 160 74 72 339 4 171 26 27 72 76 76
Onglyza 431 (25) (25) 93 (15) (16) 217 (29) 78 (24) (23) 43 (22) (22)
Bydureon 427 (2) (2) 5 25 25 343 (2) 65 (13) (12) 14 75 75
Byetta 128 (36) (35) 9 (53) (53) 81 (36) 26 (30) (27) 12 (25) (25)
Symlin 35 30 30 - - - 35 30 - - - - - -
Legacy:
Crestor 1,771 (36) (35) 577 7 10 246 (78) 514 (22) (21) 434 (2) (1)
Seloken/Toprol-XL 527 (6) (4) 437 9 12 34 (58) 48 (28) (27) 8 (20) (20)
Atacand 227 (3) (1) 135 15 19 17 (39) 63 (15) (15) 12 (20) (20)
Others 259 (16) (14) 157 (14) (9) 2 n/m 69 (22) (22) 31 (18) (18)
Total CVMD 5,327 (16) (14) 1,748 9 12 1,669 (36) 1,247 (13) (12) 663 - 1
Respiratory
Symbicort 2,051 (9) (8) 322 7 8 811 (15) 590 (13) (11) 328 6 5
Pulmicort 805 4 7 571 14 19 107 (22) 66 (10) (10) 61 - 2
Daliresp/Daxas 145 28 28 4 n/m n/m 124 23 16 60 60 1 - -
Tudorza/Eklira 108 (19) (18) - n/m n/m 47 (23) 55 (15) (14) 6 (14) (14)
Duaklir 56 27 30 - n/m n/m - - 54 23 25 2 100 100
Bevespi 8 n/m n/m - - - 8 n/m - - - - - -
Others 199 (13) (12) 68 (38) (35) 1 (86) 98 21 22 32 (3) (3)
Total Respiratory 3,372 (5) (3) 965 6 9 1,098 (13) 879 (8) (6) 430 4 4
Other
Nexium 1,525 (1) - 516 (5) (2) 442 6 176 (7) (7) 391 1 2
Synagis 453 21 21 - - - 182 6 271 33 33 - - -
Losec/Prilosec 202 (7) (5) 104 (1) 3 9 29 57 (10) (10) 32 (24) (24)
Seroquel XR 224 (64) (64) 47 (11) (11) 103 (77) 61 (42) (42) 13 (7) (7)
Movantik/Moventig 92 42 42 - n/m n/m 91 42 1 n/m n/m - - -
FluMist/Fluenz 20 (46) (46) - n/m n/m - (100) 18 (14) (14) 2 - -
Others 546 (40) (39) 311 (22) (23) 23 (77) 107 (56) (51) 105 (39) (42)
Total Other 3,062 (19) (18) 978 (11) (10) 850 (30) 691 (16) (15) 543 (12) (12)
TOTAL PRODUCT SALES 14,665 (9) (8) 4,519 5 7 4,399 (23) 3,460 (7) (6) 2,287 1 1
7 product analysis - Q3 2017
The table below provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting
year-on-year growth.
World Emerging Markets US Europe Established ROW
Q3 2017$m Actual% CER% Q3 2017$m Actual% CER Q3 2017$m Actual% Q3 2017$m Actual% CER% Q3 2017$m Actual% CER%
%
Oncology
Tagrisso 248 86 89 45 n/m n/m 97 26 48 100 96 58 107 121
Iressa 137 10 10 71 34 32 10 67 26 (13) (13) 30 (17) (11)
Lynparza 81 40 36 6 n/m n/m 37 9 36 50 54 2 n/m n/m
Imfinzi - - - - - - - - - - - - - -
Legacy:
Faslodex 241 16 16 34 48 52 127 15 61 9 4 19 6 11
Zoladex 185 (7) (6) 92 8 7 2 (75) 37 - - 54 (22) (17)
Casodex 51 (18) (16) 22 (21) (21) 1 n/m 6 - - 22 (21) (18)
Arimidex 54 (4) (2) 28 4 4 2 - 9 - - 15 (17) (11)
Others 29 7 15 8 14 29 - - 1 - - 20 5 11
Total Oncology 1,026 18 19 306 35 34 276 16 224 20 18 220 2 8
CVMD
Brilinta 284 37 36 54 20 24 140 67 78 16 12 12 - (8)
Farxiga 285 30 29 60 54 56 133 13 66 40 34 26 63 63
Onglyza 127 (25) (25) 30 - (3) 58 (37) 26 (10) (10) 13 (28) (28)
Bydureon 128 (12) (12) - n/m n/m 100 (13) 23 (8) (8) 5 67 67
Byetta 39 (36) (36) 4 (20) (20) 23 (39) 8 (33) (33) 4 (33) (33)
Symlin 10 (9) (9) - - - 10 (9) - - - - - -
Legacy:
Crestor 580 (16) (14) 188 1 3 93 (25) 152 (31) (32) 147 (8) (2)
Seloken/Toprol-XL 160 (14) (12) 148 15 16 4 (86) 6 (74) (74) 2 (60) (60)
Atacand 80 10 11 50 39 44 5 (29) 21 (16) (20) 4 (20) (20)
Others 80 (6) (5) 47 - 2 2 n/m 20 (20) (20) 11 (15) (15)
Total CVMD 1,773 (4) (4) 581 12 14 568 (8) 400 (15) (18) 224 (5) (2)
Respiratory
Symbicort 668 (4) (4) 109 17 17 257 (7) 191 (10) (12) 111 (3) (1)
Pulmicort 242 8 9 175 15 16 29 (9) 18 (5) (11) 20 (5) -
Daliresp/Daxas 53 26 26 1 n/m n/m 45 29 7 17 17 - n/m n/m
Tudorza/Eklira 37 (21) (21) - - - 18 (10) 17 (29) (29) 2 (33) (33)
Duaklir 21 50 43 - n/m n/m - - 20 25 19 1 n/m n/m
Bevespi 4 n/m n/m - - - 4 n/m - - - - - -
Others 67 (22) (22) 21 (45) (45) (1) n/m 37 19 19 10 (41) (41)
Total Respiratory 1,092 (2) (2) 306 9 10 352 (3) 290 (6) (8) 144 (8) (6)
Other
Nexium 469 (9) (7) 172 (2) - 103 (17) 56 (11) (16) 138 (9) (4)
Synagis 153 47 47 - - - 15 88 138 44 44 - - -
Losec/Prilosec 66 (8) (8) 34 3 6 1 (50) 19 (14) (18) 12 (20) (20)
Seroquel XR 62 (67) (68) 15 (17) (22) 26 (81) 18 (40) (40) 3 (25) (25)
Movantik/Moventig 30 20 20 - n/m n/m 29 21 1 n/m n/m - - -
FluMist/Fluenz 20 (23) (23) - n/m n/m - (100) 18 (14) (14) 2 - -
Others 191 (30) (29) 101 (28) (23) 16 (32) 24 (65) (69) 50 11 11)
Total Other 991 (18) (17) 322 (13) (10) 190 (41) 274 (8) (10) 205 (6) (2)
TOTAL PRODUCT SALES 4,882 (3) (2) 1,515 9 10 1,386 (10) 1,188 (6) (8) 793 (4) -
8 QUARTERLY PRODUCT SALES - 2017
The table below provides an analysis of sequential quarterly Product Sales, with Actual and CER growth rates reflecting
quarter-on-quarter growth.
Q1 2017$m Actual% CER% Q2 2017$m Actual% CER Q3 2017$m Actual% CER%
%
Oncology
Tagrisso 171 16 19 232 36 34 248 7 5
Iressa 124 5 8 137 10 9 137 - (1)
Lynparza 57 (8) (6) 59 4 2 81 37 33
Imfinzi - - - 1 n/m n/m - - -
Legacy:
Faslodex 214 (4) (3) 248 16 15 241 (3) (5)
Zoladex 185 (21) (12) 178 (4) (5) 185 4 2
Casodex 56 (7) (2) 54 (4) (3) 51 (6) (9)
Arimidex 52 (9) (7) 54 4 4 54 - (2)
Others 26 (10) (3) 30 15 7 29 (3) (3)
Total Oncology 885 (5) -
- More to follow, for following part double click ID:nRSI9871VeRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement